The latest price target for BioNTech (NASDAQ:BNTX) was reported by Goldman Sachs on January 16, 2026. The analyst firm set a price target for $142.00 expecting BNTX to rise to within 12 months (a possible 24.56% upside). 28 analyst firms have reported ratings in the last year.

The latest analyst rating for BioNTech (NASDAQ:BNTX) was provided by Goldman Sachs, and BioNTech upgraded their buy rating.

The last upgrade for BioNTech SE happened on January 16, 2026 when Goldman Sachs raised their price target to $142. Goldman Sachs previously had a neutral for BioNTech SE.

The last downgrade for BioNTech SE happened on December 1, 2023 when JP Morgan changed their price target from $106 to $99 for BioNTech SE.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioNTech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioNTech was filed on January 16, 2026 so you should expect the next rating to be made available sometime around January 16, 2027.

While ratings are subjective and will change, the latest BioNTech (BNTX) rating was a upgraded with a price target of $115.00 to $142.00. The current price BioNTech (BNTX) is trading at is $114.00, which is out of the analyst’s predicted range.